Researchers develop microfluidic chip to stem flu outbreaks

The chip accepts a nasal specimen, extracts influenza A RNA, converts it into DNA and replicates it to yield a sufficient sample that can be detected by an external reader. Credit: Boston University

The H1N1 flu pandemic in 2009 underscored weaknesses in methods widely used to diagnose the flu, from frequent false negatives to long wait times for results. Now Boston University researchers have developed a prototype of a rapid, low-cost, accurate, point-of-care device that promises to provide clinicians with an effective tool to quickly diagnose both seasonal and pandemic strains of influenza, and thus limit the spread of infection.

Boston University Biomedical Engineering Associate Professor Catherine Klapperich led the team of engineering and medical researchers that developed the disposable microfluidic chip the size of a that aims to take the place of expensive, time-consuming, laboratory-based diagnostic tests now in use. The chip essentially miniaturizes the RT-PCR test, now considered the gold standard in flu detection, producing faster, cheaper and accurate results.

The researchers collected clinical nasal specimens and placed them on the chip, which extracts RNA from the , converts it into DNA and replicates the sample in sufficient quantities so it can be detected by a table-top external reader. The chip produced results that matched the accuracy of the lab-based tests.

"We wanted to show that our technique was feasible on real-world samples prepared on the chip," said Klapperich. "Making each chip single-use decreases the possibility of cross-contamination between specimens, and the chip's small size makes it a good candidate for true point-of-care testing."

The microfluidic also proved far more effective than other commonly used flu including viral culture, a lab procedure requiring up to a week to produce results; rapid immunoassays, which work like pregnancy tests but were only 40 percent reliable in detecting the presence of a flu virus in this study; and direct fluorescent antigen testing (DFA), a more accurate but labor-intensive process in which medical personnel prepare and interpret samples stained with fluorescent antibodies.

"The new test represents a major improvement over viral culture in terms of turn-around time, over rapid immunoassay tests in terms of sensitivity (ability to detect the virus from minimal sample material) and over DFA and RT-PCR in terms of ease of use and portability," Klapperich observed.

Ultimately seeking to enable clinicians to use their microfluidic chips for frontline detection, the researchers next plan to optimize their method so that it can produce results in a third less time (an hour) with chips that cost half as much to make (five dollars). In addition, they are exploring ways to develop a lower cost external reader that's no bigger than a clinical digital thermometer.

More information: The results were published in the March 22 online edition of PLoS ONE.

Journal reference: PLoS ONE search and more info website

Provided by Boston University College of Engineering

5 /5 (3 votes)

Related Stories

Rapid flu testing

Dec 29, 2009

Researchers from the Medical College of Wisconsin, the Children's Research Institute, and the Children's Hospital of Wisconsin have developed a rapid, automated system to differentiate strains of influenza. The related report ...

Biosensors: A handy kit

Apr 14, 2011

(PhysOrg.com) -- A silicon-based microfluidic chip that distinguishes different viral strains shows potential for the quick on-site diagnosis of infectious diseases.

DFA unreliable in H1N1 testing in critically ill patients

May 17, 2010

Direct Immunofluorescence Assay (DFA) testing for H1N1 influenza ("swine flu") is unreliable in ICU patients, according to a new study from Stanford University. Multiple methods exist for diagnosing influenza, but data on ...

Researchers use gold nanoparticles to diagnose flu in minutes

Aug 04, 2011

Arriving at a rapid and accurate diagnosis is critical during flu outbreaks, but until now, physicians and public health officials have had to choose between a highly accurate yet time-consuming test or a rapid but error-prone ...

Recommended for you

How Alzheimer's peptides shut down cellular powerhouses

5 hours ago

The failing in the work of nerve cells: An international team of researchers led by Prof. Dr. Chris Meisinger from the Institute of Biochemistry and Molecular Biology of the University of Freiburg has discovered ...

User comments